Keyphrases
Pembrolizumab
100%
Tumor
45%
MD Anderson Cancer Center
43%
Immune Checkpoint Inhibitors
38%
Stable Disease
33%
Immune Cells
31%
Phase II Clinical Trial
31%
Treatment Outcome
30%
Center Experience
29%
Advanced Solid Tumors
29%
Selinexor
29%
Clinical Trials
24%
Basket Trial
24%
Programmed Death-ligand 1 (PD-L1)
23%
Rare Cancer
23%
Objective Response Rate
23%
Partial Response
22%
Basic Immunology
21%
Response-outcome
21%
Phase Ib Study
21%
Adverse Events
19%
Clinical Benefit Rate
19%
In Cancer
19%
Rare Tumors
18%
Translational Relevance
18%
Predictive Biomarker
18%
Non-progression
18%
Tumor Microenvironment
17%
Immune-related Adverse Events
17%
Immune Response
17%
Cancer Patients
16%
Progression-free Survival
15%
Progression Rate
15%
Targeted Agents
15%
Carboplatin
15%
Single Center
15%
Improved Outcomes
15%
Overall Survival
15%
T Cells
15%
Confidence Interval
14%
Invasive Margin
14%
Surveillance System
14%
B Cells
14%
Evade
14%
Human Immune System
14%
Immune Therapeutics
14%
Immune Milieu
14%
Neutrophils
14%
Mast Cells
14%
Tumor Immune Surveillance
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
85%
Diseases
61%
Neoplasm
61%
Clinical Trial
59%
Malignant Neoplasm
55%
Solid Malignant Neoplasm
46%
Adverse Event
37%
Selinexor
29%
Immunotherapy
26%
Immune Checkpoint Inhibitor
22%
Progression Free Survival
20%
Overall Survival
19%
Advanced Cancer
18%
Epidermal Growth Factor Receptor
16%
Carboplatin
15%
Paclitaxel
14%
Non Small Cell Lung Cancer
12%
Combination Therapy
11%
Vasculotropin
10%
Remission
10%
Ovary Cancer
10%
Breast Cancer
9%
Endometrium Cancer
9%
Tolerability
9%
Connective Tissue Cancer
9%
Anemia
9%
Mammalian Target of Rapamycin Inhibitor
9%
Thrombocytopenia
8%
Diarrhea
8%
Lung Cancer
7%
Antitumor Activity
7%
Anticancer Drug
7%
Spartalizumab
7%
Skin Carcinoma
7%
Pazopanib
7%
Cytotoxic Agent
7%
Cancer of Unknown Primary Site
7%
Placebo
7%
Granulosa Cell Tumour
7%
Everolimus
7%
Randomized Clinical Trial
7%
Glutamine
7%
Avelumab
7%
Aflibercept
7%
Pheochromocytoma
7%
Adrenal Cortex Carcinoma
7%
Sapanisertib
7%
Nasopharynx Carcinoma
7%
Immunotherapy Clinical Trial
7%
Virus Hepatitis
7%
Medicine and Dentistry
Pembrolizumab
91%
Clinical Trial
56%
Neoplasm
50%
Cancer
46%
Malignant Neoplasm
39%
Diseases
38%
Immunotherapy
34%
Immune Checkpoint Inhibitor
29%
Rare Tumor
20%
Adverse Event
18%
Progression Free Survival
17%
Squamous Cell Carcinoma
17%
Biopsy Technique
15%
Overall Survival
15%
Systematic Review
14%
Hazard Ratio
12%
Immunity
11%
Cancer of Unknown Primary Origin
10%
Pheochromocytoma
10%
Paraganglioma
10%
Adrenal Cortex Carcinoma
10%
Mammalian Target of Rapamycin Inhibitor
10%
Next Generation Sequencing
10%
Targeted Therapy
10%
Systemic Therapy
10%
Programmed Death-Ligand 1
8%
Comprehensive Genomic Profiling
8%
Epidermal Growth Factor Receptor
8%
Advanced Cancer
8%
Programmed Cell Death
7%
Exanthem
7%
Cancer Metabolism
7%
Penis Cancer
7%
Triple Negative Breast Cancer
7%
Glutamine
7%
Anticarcinogen
7%
Combination Chemotherapy
7%
Uterine Cancer
7%
Tumor Progression
7%
Tumor Biopsy
7%
Cancer Therapy
7%
Lethality
7%
Granulosa Cell Tumour
7%
Vasculotropin
7%
Immunotherapy Clinical Trial
7%
Infusion
7%
Retrospective Cohort Study
7%
Thymus Cancer
7%
Meta-Analysis
7%
Placebo
7%